secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001396814-23-000077
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q3 net income $10.9M, cuts FY EXPAREL guidance; CEO Stack to retire
--------------------------------------------------------------------------

- Total revenues $163.9M, down ~2% YoY; EXPAREL sales $128.7M, down from $132.6M.
- GAAP net income $10.9M ($0.23/sh) vs net loss $0.7M in Q3 2022; adjusted EBITDA $52.9M.
- Lowers FY 2023 EXPAREL net product sales guidance to $535-540M from prior $550-560M.
- CEO Dave Stack will retire; remains until successor appointed, then consulting through Aug 2025.
- PDUFA action date for EXPAREL lower extremity nerve block on track for Nov 13, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/0001396814-23-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000077/pcrx-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001396814-23-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer